Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Electrophysiological and Pharmacological Characterization of Human Inwardly Rectifying Kir2.1 Channels on an Automated Patch-Clamp Platform.

Sanson C, Schombert B, Filoche-Rommé B, Partiseti M, Bohme GA.

Assay Drug Dev Technol. 2019 Apr;17(3):89-99. doi: 10.1089/adt.2018.882. Epub 2019 Mar 5.

2.

Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.

Houtmann S, Schombert B, Sanson C, Partiseti M, Bohme GA.

Methods Mol Biol. 2017;1641:187-199. doi: 10.1007/978-1-4939-7172-5_10.

PMID:
28748465
3.

Fragmentation transitions in multistate voter models.

Böhme GA, Gross T.

Phys Rev E Stat Nonlin Soft Matter Phys. 2012 Jun;85(6 Pt 2):066117. Epub 2012 Jun 15.

PMID:
23005172
4.

Early fragmentation in the adaptive voter model on directed networks.

Zschaler G, Böhme GA, Seißinger M, Huepe C, Gross T.

Phys Rev E Stat Nonlin Soft Matter Phys. 2012 Apr;85(4 Pt 2):046107. Epub 2012 Apr 13.

PMID:
22680538
5.

Analytical calculation of fragmentation transitions in adaptive networks.

Böhme GA, Gross T.

Phys Rev E Stat Nonlin Soft Matter Phys. 2011 Mar;83(3 Pt 2):035101. Epub 2011 Mar 23.

PMID:
21517549
6.

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.

Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B.

Neuropsychopharmacology. 2007 Jan;32(1):1-16. Epub 2006 Oct 4.

7.

1400W, a potent selective inducible NOS inhibitor, improves histopathological outcome following traumatic brain injury in rats.

Jafarian-Tehrani M, Louin G, Royo NC, Besson VC, Bohme GA, Plotkine M, Marchand-Verrecchia C.

Nitric Oxide. 2005 Mar;12(2):61-9. Epub 2005 Jan 21.

PMID:
15740979
8.

An in vitro and in vivo study of early deficits in associative learning in transgenic mice that over-express a mutant form of human APP associated with Alzheimer's disease.

Domínguez-del-Toro E, Rodríguez-Moreno A, Porras-García E, Sánchez-Campusano R, Blanchard V, Laville M, Böhme GA, Benavides J, Delgado-García JM.

Eur J Neurosci. 2004 Oct;20(7):1945-52.

PMID:
15380017
9.

Heterologous expression of human {alpha}6{beta}4{beta}3{alpha}5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the {alpha}5 subunit.

Grinevich VP, Letchworth SR, Lindenberger KA, Menager J, Mary V, Sadieva KA, Buhlman LM, Bohme GA, Pradier L, Benavides J, Lukas RJ, Bencherif M.

J Pharmacol Exp Ther. 2005 Feb;312(2):619-26. Epub 2004 Sep 8.

PMID:
15356217
10.

TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.

Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M.

CNS Drug Rev. 2004 Summer;10(2):147-66. Review.

11.

Synthesis of a [2-pyridinyl-18F]-labelled fluoro derivative of (-)-cytisine as a candidate radioligand for brain nicotinic alpha4beta2 receptor imaging with PET.

Roger G, Lagnel B, Rouden J, Besret L, Valette H, Demphel S, Gopisetti J, Coulon C, Ottaviani M, Wrenn LA, Letchworth SR, Bohme GA, Benavides J, Lasne MC, Bottlaender M, Dollé F.

Bioorg Med Chem. 2003 Dec 1;11(24):5333-43.

PMID:
14642577
12.

Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse.

Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, Laville M, Pratt J, Corti O, Pradier L, Ret G, Joubert C, Periquet M, Araujo F, Negroni J, Casarejos MJ, Canals S, Solano R, Serrano A, Gallego E, Sanchez M, Denefle P, Benavides J, Tremp G, Rooney TA, Brice A, Garcia de Yebenes J.

Hum Mol Genet. 2003 Sep 15;12(18):2277-91. Epub 2003 Jul 22.

PMID:
12915482
13.

Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice.

Douhou A, Debeir T, Murer MG, Do L, Dufour N, Blanchard V, Moussaoui S, Bohme GA, Agid Y, Raisman-Vozari R.

Exp Neurol. 2002 Jul;176(1):247-53.

PMID:
12093102
14.

9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocylic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist.

Mignani S, Bohme GA, Birraux G, Boireau A, Jimonet P, Damour D, Genevois-Borella A, Debono MW, Pratt J, Vuilhorgne M, Wahl F, Stutzmann JM.

Bioorg Med Chem. 2002 May;10(5):1627-37.

PMID:
11886824
15.

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain.

Hassani OK, Mouroux M, Bohme GA, Stutzmann JM, Féger J.

Mov Disord. 2001 Nov;16(6):1110-4.

PMID:
11748743
16.

RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis.

Canton T, Böhme GA, Boireau A, Bordier F, Mignani S, Jimonet P, Jahn G, Alavijeh M, Stygall J, Roberts S, Brealey C, Vuilhorgne M, Debono MW, Le Guern S, Laville M, Briet D, Roux M, Stutzmann JM, Pratt J.

J Pharmacol Exp Ther. 2001 Oct;299(1):314-22.

PMID:
11561094
17.

Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz.

Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S.

Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10.

PMID:
11354378
18.

Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.

Jimonet P, Bohme GA, Bouquerel J, Boireau A, Damour D, Debono MW, Genevois-Borella A, Hardy JC, Hubert P, Manfré F, Nemecek P, Pratt J, Randle JC, Ribeill Y, Stutzmann JM, Vuilhorgne M, Mignani S.

Bioorg Med Chem Lett. 2001 Jan 22;11(2):127-32.

PMID:
11206442
19.

Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.

Cossu G, Ledent C, Fattore L, Imperato A, Böhme GA, Parmentier M, Fratta W.

Behav Brain Res. 2001 Jan 8;118(1):61-5.

PMID:
11163634
20.

Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia-induced brain injury.

Parmentier-Batteur S, Bohme GA, Lerouet D, Zhou-Ding L, Beray V, Margaill I, Plotkine M.

J Cereb Blood Flow Metab. 2001 Jan;21(1):15-21.

PMID:
11149663
21.

Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.

Pratt J, Jimonet P, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Randle JC, Ribeill Y, Stutzmann JM, Vuilhorgne M, Mignani S.

Bioorg Med Chem Lett. 2000 Dec 18;10(24):2749-54.

PMID:
11133083
22.

Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn).

Kennel P, Revah F, Bohme GA, Bejuit R, Gallix P, Stutzmann JM, Imperato A, Pratt J.

J Neurol Sci. 2000 Nov 1;180(1-2):55-61.

PMID:
11090865
23.

8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e] pyrazine-4-ones: highly in vivo potent and selective AMPA receptor antagonists.

Jimonet P, Chevé M, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Imperato A, Pratt J, Randle JC, Ribeill Y, Stutzmann JM, Vuilhorgne M, Mignani S.

Bioorg Med Chem. 2000 Aug;8(8):2211-7.

PMID:
11003165
24.

Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity.

Jimonet P, Ribeill Y, Bohme GA, Boireau A, Chevé M, Damour D, Doble A, Genevois-Borella A, Herman F, Imperato A, Le Guern S, Manfré F, Pratt J, Randle JC, Stutzmann JM, Mignani S.

J Med Chem. 2000 Jun 15;43(12):2371-81.

PMID:
10882363
25.

4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity.

Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Mignani S.

Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.

PMID:
10843235
26.

8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists.

Mignani S, Bohme GA, Boireau A, Cheve M, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JC, Ribeill Y, Vuilhorgne M, Stutzmann JM.

Bioorg Med Chem Lett. 2000 Mar 20;10(6):591-6.

PMID:
10741560
27.

Cloning of rat parkin cDNA and distribution of parkin in rat brain.

Gu WJ, Abbas N, Lagunes MZ, Parent A, Pradier L, Bohme GA, Agid Y, Hirsch EC, Raisman-Vozari R, Brice A.

J Neurochem. 2000 Apr;74(4):1773-6.

28.

Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors.

Bohme GA, Laville M, Ledent C, Parmentier M, Imperato A.

Neuroscience. 2000;95(1):5-7.

PMID:
10619457
29.

Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice.

Mascia MS, Obinu MC, Ledent C, Parmentier M, Böhme GA, Imperato A, Fratta W.

Eur J Pharmacol. 1999 Nov 3;383(3):R1-2.

PMID:
10594337
30.

The effect of riluzole and mannitol on cerebral oedema after cryogenic injury in the mouse.

Pratt J, Archambaud C, Böhme GA, Roux M, Rataud J, Imperato A, Stutzmann JM.

Neurosci Lett. 1999 Sep 17;272(3):143-5.

PMID:
10505601
31.

Enhancement of memory in cannabinoid CB1 receptor knock-out mice.

Reibaud M, Obinu MC, Ledent C, Parmentier M, Böhme GA, Imperato A.

Eur J Pharmacol. 1999 Aug 20;379(1):R1-2.

PMID:
10499380
32.

Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury.

Parmentier S, Böhme GA, Lerouet D, Damour D, Stutzmann JM, Margaill I, Plotkine M.

Br J Pharmacol. 1999 May;127(2):546-52.

33.

A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.

Abbas N, Lücking CB, Ricard S, Dürr A, Bonifati V, De Michele G, Bouley S, Vaughan JR, Gasser T, Marconi R, Broussolle E, Brefel-Courbon C, Harhangi BS, Oostra BA, Fabrizio E, Böhme GA, Pradier L, Wood NW, Filla A, Meco G, Denefle P, Agid Y, Brice A.

Hum Mol Genet. 1999 Apr;8(4):567-74.

PMID:
10072423
34.

Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M.

Science. 1999 Jan 15;283(5400):401-4.

35.

Calretinin expression as a critical component in the control of dentate gyrus long-term potentiation induction in mice.

Gurden H, Schiffmann SN, Lemaire M, Böhme GA, Parmentier M, Schurmans S.

Eur J Neurosci. 1998 Sep;10(9):3029-33.

PMID:
9758174
36.

Impaired long-term potentiation induction in dentate gyrus of calretinin-deficient mice.

Schurmans S, Schiffmann SN, Gurden H, Lemaire M, Lipp HP, Schwam V, Pochet R, Imperato A, Böhme GA, Parmentier M.

Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10415-20.

37.

Electrographic studies of the effects of RP 60180, a novel kappa agonist, on the photosensitive baboon Papio papio.

Stutzmann JM, Valin A, Böhme GA, Fardin V, Garret C, Naquet R.

Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jul;19(4):687-97.

PMID:
8588066
38.

Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.

Bertrand P, Böhme GA, Durieux C, Guyon C, Capet M, Jeantaud B, Boudeau P, Ducos B, Pendley CE, Martin GE, et al.

Eur J Pharmacol. 1994 Sep 12;262(3):233-45.

PMID:
7813588
39.

CCK-A and CCK-B receptors enhance olfactory recognition via distinct neuronal pathways.

Lemaire M, Barnéoud P, Böhme GA, Piot O, Haun F, Roques BP, Blanchard JC.

Learn Mem. 1994 Sep-Oct;1(3):153-64.

PMID:
10467593
40.

CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats.

Lemaire M, Böhme GA, Piot O, Roques BP, Blanchard JC.

Psychopharmacology (Berl). 1994 Aug;115(4):435-40.

PMID:
7871086
41.

The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists.

Böhme GA, Bertrand P, Guyon C, Capet M, Pendley C, Stutzmann JM, Doble A, Dubroeucq MC, Martin G, Blanchard JC.

Ann N Y Acad Sci. 1994 Mar 23;713:118-20. No abstract available.

PMID:
8185152
42.

Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats.

Böhme GA, Bon C, Lemaire M, Reibaud M, Piot O, Stutzmann JM, Doble A, Blanchard JC.

Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9191-4.

43.

[Cholecystokinins and their receptors. Functional aspects].

Böhme GA, Blanchard JC.

Therapie. 1992 Nov;47(6):541-8. Review. French.

PMID:
1301646
44.

Evidence for an endogenous cholecystokininergic balance in social memory.

Lemaire M, Piot O, Roques BP, Böhme GA, Blanchard JC.

Neuroreport. 1992 Oct;3(10):929-32.

PMID:
1421101
45.

CholecystokininA and cholecystokininB receptors in neurons of the brainstem solitary complex of the rat: pharmacological identification.

Branchereau P, Böhme GA, Champagnat J, Morin-Surun MP, Durieux C, Blanchard JC, Roques BP, Denavit-Saubié M.

J Pharmacol Exp Ther. 1992 Mar;260(3):1433-40.

PMID:
1545402
46.

A Role for Nitric Oxide in Long-term Potentiation.

Bon C, Böhme GA, Doble A, Stutzmann JM, Blanchard JC.

Eur J Neurosci. 1992;4(5):420-424.

PMID:
12106350
47.

Possible involvement of nitric oxide in long-term potentiation.

Böhme GA, Bon C, Stutzmann JM, Doble A, Blanchard JC.

Eur J Pharmacol. 1991 Jul 9;199(3):379-81.

PMID:
1915585
48.

'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.

Rataud J, Darche F, Piot O, Stutzmann JM, Böhme GA, Blanchard JC.

Brain Res. 1991 May 10;548(1-2):315-7.

PMID:
1868342
49.

Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat.

Stutzmann JM, Böhme GA, Gandolfo G, Gottesmann C, Lafforgue J, Blanchard JC, Laduron PM, Lazdunski M.

Eur J Pharmacol. 1991 Feb 7;193(2):223-9.

PMID:
2050198
50.

Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264.

Dauge V, Bohme GA, Crawley JN, Durieux C, Stutzmann JM, Feger J, Blanchard JC, Roques BP.

Synapse. 1990;6(1):73-80.

PMID:
2399491

Supplemental Content

Loading ...
Support Center